A time-resolved fluorescence kit for synchronously detecting 4,15-diacetoxyscirpenol, deoxynivalenol and T-2 toxin. The kit includes an immunochromatography time-resolved fluorescence test strip and a sample reaction bottle containing freeze-dried products of europium-labeled monoclonal antibodies of toxins, where the immunochromatography time-resolved fluorescence test strip includes a liner, where a water absorption pad, a detection pad and a sample pad are sequentially attached to one side of the liner from top to bottom, adjacent pads are connected in an overlapping manner at a joint, the detection pad uses a nitrocellulose membrane as a base pad, a transverse quality control line and detection lines are arranged on the nitrocellulose membrane from top to bottom, the quality control line is coated with a rabbit antimouse polyclonal antibody, the three detection lines are located below the quality control line, and the detection lines each are coated with a toxin-protein conjugate.

A test strip and kit for testing mycophenolic acid and a preparation method of the test strip are described. The test strip includes a bottom plate and a sample pad, a glassfiber membrane, a nitrocellulose membrane and an absorbent paper which are successively lapped on a surface of the bottom plate, the sample pad is treated by a sample pad treatment fluid; the glassfiber membrane is treated by a glassfiber membrane treatment fluid; the glassfiber membrane is coated by a mycophenolic acid specific-antibody conjugate; the nitrocellulose membrane is provided with a detection line and a quality control line; and a mycophenolic acid protein conjugate is sprayed on the detection line.

A test kit for detecting organophosphate compounds, includes a support apparatus, a sampling device, a buffer solution in a sample tube, and an acetylcholinesterase as the first active component and a mixture of 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and acetylthiocholine. The sampling device is packaged in a sample tube, where the first active component is applied in a first reagent cap and the second active component is applied in a second reagent cap, and the first and second reagent caps each seal a sample tube. The support apparatus has at least four fixing devices for receiving the sample tubes. The sample tubes are fixed parallel to the upper side of the support apparatus, and the support apparatus has at least two receiving devices for receiving the first and second reagent caps and one receiving device for vertically receiving a sample tube.

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

A method is described of manufacturing an optical sensing element for detecting a presence and/or determining a concentration of an analyte in a fluid medium, in particular in an aqueous medium. The optical sensing element includes an optical waveguide (e.g. an optical fiber) comprising an optically transparent material for guiding light through the sensing element along a flightpath. The optical sensing element further includes an inorganic coating for adsorbing the analyte from the fluid medium and an adhesion promotion layer formed between the optical waveguide and the inorganic coating. The adhesion promotion layer includes an adhesion promotion material for promoting adhesion of the inorganic material.

A method for evaluating a mass spectrometry device includes: by a mass spectrometry device, performing mass spectrometry of an ester of phthalic acid and detecting a plurality of types of ions produced by dissociation of the ester of phthalic acid; and obtaining information concerning whether the mass spectrometry device is in a state suitable for analysis, based on a ratio of intensities of the plurality of types of ions detected.

The present invention provides methods for analyzing a target compound from a biological sample. In one aspect, a method for analyzing a target compound in a biological sample can comprise delivering a biological sample through an affinity column, the affinity column having a binding ligand coupled to a stationary structural support, wherein the affinity column has a high density of the binding ligand per the stationary structural support and wherein the binding ligand has been preselected to cause weak affinity separation zonal retardation of the target compound from the biological sample forming a target compound fraction and a biological sample fraction and detecting the target compound by mass spectrometry.

An immunoassay method for detecting and determining ‘NBOMe’ family designer drugs is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.

Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.